Sanofi's SERD Candidate Founders In Advanced Breast Cancer
But Hope Remains For Earlier Setting
The French major’s amcenestrant has missed its primary endpoint in a Phase II study of advanced breast cancer patients but could still have potential in earlier adjuvant disease.
